Philadelphia - October 27, 2026 - Proscia has entered into a collaborative agreement with Columbia University to identify biomarkers for neurodegenerative diseases, such as Alzheimer’s and other dementias. The collaboration pairs Columbia’s pathology leadership and digital slide repository with Proscia’s deep pathology AI expertise.
“Collaborating with Proscia will enable us to leverage numerous data streams and integrate multiple forms of imaging and clinical data to uncover new insight into neurodegenerative diseases,” said Kevin L. Gardner, MD, PhD, Chair of the Department of Pathology and Cell Biology at Columbia University Vagelos College of Physicians and Surgeons and Pathologist-in-Chief at NewYork-Presbyterian/Columbia University Irving Medical Center. “Ultimately, we hope that the collaboration will drive new discoveries that link biomarker and therapeutic development.”
In addition to identifying new biomarkers for neurodegenerative diseases, Columbia and Proscia will validate established biomarkers. These biomarkers may be semi-quantitative manual scores and composite multiplex scores derived from automated analysis of co-registered serial stains.
Proscia’s Concentriq® platform will serve as the foundation for the work, with Proscia’s Aperture network providing a path for additional collaboration with drug developers, including 16 of the top 20 pharmaceutical companies.
“In today’s precision medicine era, pathology will drive the most meaningful breakthroughs when data, technology, and expertise come together,” said Nathan Buchbinder, Chief Strategy Officer of Proscia. “Columbia is world-renowned for its pathology leadership, research, and patient care, and we look forward to demonstrating what’s possible together.”
About Proscia
Proscia is the pathology AI company rewiring pathology for precision medicine across drug discovery, development, and diagnosis. Its Concentriq platform brings intelligence to the scientists, pathologists, and laboratory leaders behind the most critical decisions in medicine, helping more breakthroughs reach the patients they were made for. Proscia is trusted by 16 of the top 20 pharmaceutical companies and was named Global 2026 Best in KLAS for Digital Pathology in Europe. Learn more at proscia.com, and follow Proscia on LinkedIn and X.